Scientists test new drug cocktail for blood cancer

NCT ID NCT05050097

Summary

This early-stage study aims to find safe doses and check side effects when combining the investigational drug talquetamab with other approved myeloma treatments. It involves 166 participants who have multiple myeloma that has returned or stopped responding to prior therapies. The main goal is to understand the safety of these drug combinations before testing how well they work in later studies.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Alfred Health

    Melbourne, 3004, Australia

  • CHU Nantes

    Nantes, 44093, France

  • CHU de Bordeaux - Hospital Haut-Leveque

    Pessac, 33604, France

  • Chu Rennes Hopital Pontchaillou

    Rennes, 35000, France

  • Churchill Hospital

    Oxford, OX3 7LE, United Kingdom

  • Cliniques Universitaires St-Luc

    Brussels, 1200, Belgium

  • Colorado Blood Cancer Institute

    Denver, Colorado, 80218, United States

  • Emory University

    Atlanta, Georgia, 30322, United States

  • Gold Coast University Hospital

    Southport, 4215, Australia

  • Hackensack University Medical Center

    Hackensack, New Jersey, 07601, United States

  • Indiana University

    Indianapolis, Indiana, 46202, United States

  • Institut Universitaire du cancer de Toulouse-Oncopole

    Toulouse, 31059, France

  • Levine Cancer Institute

    Charlotte, North Carolina, 28204, United States

  • Maastricht University Medical Centre

    Maastricht, 6229 HX, Netherlands

  • Medical College Of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Mt. Sinai School of Medicine

    New York, New York, 10029, United States

  • St Vincents Hospital Melbourne

    Fitzroy, 3065, Australia

  • Tennessee Oncology

    Nashville, Tennessee, 37203, United States

  • The Christie Nhs Foundation Trust

    Manchester, M20 4BX, United Kingdom

  • The Royal Marsden NHS Trust Sutton

    Surrey, SM2 5PT, United Kingdom

  • UMCG

    Groningen, 9713 GZ, Netherlands

  • UMCU

    Utrecht, 3584 CX, Netherlands

  • UZ Gent

    Ghent, 9000, Belgium

  • UZ Leuven

    Leuven, 3000, Belgium

  • UZA

    Edegem, 2650, Belgium

  • University College Hospital London

    London, W1T 7HA, United Kingdom

  • University of Alabama Birmingham

    Birmingham, Alabama, 35294, United States

  • University of California San Francisco

    San Francisco, California, 94143, United States

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15232, United States

  • Weill Cornell Medical College

    New York, New York, 10065, United States

  • Wollongong Hospital

    Wollongong, 2500, Australia

Conditions

Explore the condition pages connected to this study.